Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis.

PLoS One · 2015 · PMC4352054 · PMID 25747279

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantp = 0.05actually significant

However, a two-way ANOVA with repeated measures showed only a marginally significant effect of Time (p = 0.05), but no Time*Treatment interaction (p = 0.19).

also in 26,082 other papers

showed a trendno p-value reported

We conclude that PF-01247324 showed a trend toward slightly improved symptoms in the EAE model, but the effect size was small and not statistically distinguishable from vehicle.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.